June 12 – 17, 2022
Bartonella bacilliformis is the causative agent of Carrion’s disease, this illness affects poor communities of Andean valleys (Peru, Colombia and Ecuador) . B. bacilliformis produces a biphasic infection: acute phase presents severe anemia and immunosuppression, and chronic phase involves dermal eruption . Currently, the available tools for the diagnosis of Carrion’s disease include low sensitive serological assays and expensive molecular tools . To improve the diagnosis, this project aims to produce monoclonal antibodies specific soluble proteins of B. bacilliformis. The monoclonal antibodies production was performed immunizing three Balb/C mice with soluble proteins obtained from the total lysate of B. bacilliformis. The immune response was tested by ELISA at a serum dilution of 1:500 and 1:8000, seropositive animals were sacrificed to obtain B lymphocytes from the spleen. The B lymphocytes were fused with Ag8 myeloma cells in HAT medium, the obtained hybridomas were cloned. ELISA evaluation was performed for the selection of the monoclonal-antibody producing clones. The optical densities and antibody titers were analyzed using the statistical package SPSS. 21. The sera titer of immunized mice was equivalent to 0.8-1.0 OD at 1:8000 dilution, whilst the OD of the medium of the hybridomas was 0.2-2.0 (FIG. 1). Clones displaying higher density were growth upon reach OD of 2.0. Monoclonal antibodies were successfully produced, but antibody identification is pending evaluation.
Please click Download on the upper right corner to see the full abstract.
Yanina Zarate Sulca, Yolanda Medina, Karen D. Calvay Sanchez, and Giovanna Mendonza Mujica, "Production of monoclonal antibodies specific to soluble proteins of Bartonella bacilliformis" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/91